PMID- 25170796
OWN - NLM
STAT- MEDLINE
DCOM- 20150825
LR  - 20151119
IS  - 1423-0399 (Electronic)
IS  - 0042-1138 (Linking)
VI  - 93
IP  - 4
DP  - 2014
TI  - Comparative effectiveness of combined low- and standard-dose trospium and 
      solifenacin for moderate overactive bladder symptoms in elderly men and women.
PG  - 470-3
LID - 10.1159/000363658 [doi]
AB  - OBJECTIVE: To increase the safety and effectiveness of treatments for overactive 
      bladder (OAB) with moderate symptoms in elderly patients. PATIENTS AND METHODS: 
      Patients were examined at the Urodynamic Department of the Regional Diagnostic 
      Center (Vladivostok, Russian Federation) from September 1, 2012 to December 31, 
      2012. The assignment of patients [n = 177, average age 69. 4 years, 98 women 
      (55.4%) and 79 men (44.6%)] was random and blind in this placebo-controlled 
      study. Patients were distributed into subgroups according to the method of 
      treatment as follows: group capital A, Cyrillic1: n = 57, trospium 30 mg/day + solifenacin 10 
      mg/day; group capital A, Cyrillic2: n = 61, trospium 15 mg/day + solifenacin 5 mg/day; group capital A, Cyrillic3: n 
      = 59, placebo. All patients underwent a urodynamic examination in accordance with 
      international standards before and 2 months after treatment. ICIQ-SF 
      questionnaires recommended by the International Continence Society (ICS) and 
      bladder diaries were used to evaluate the clinical results. The clinical severity 
      of the OAB symptoms and the effectiveness of the treatment were evaluated based 
      on the frequency of episodes of incontinence (EI) per day. Three or fewer EI per 
      day were considered moderate dysfunction of the lower urinary tract. RESULTS: 
      Groups of elderly patients with moderate symptoms of OAB who were treated with 
      standard- and low-dose trospium and solifenacin demonstrated a significant 
      increase in the median values of reflex volume, bladder capacity, and detrusor 
      compliance and a decrease in the frequency of urination and urinary urgencies. 
      The frequency of EI in both of the main groups decreased by almost 2-fold in 
      comparison to the initial data and reached the following values: group capital A, Cyrillic1: 1.27 
      (-1.08), p </= 0.05; group A2: 1.49 (-1.18), p </= 0.05. The correlation with the 
      decrease in the frequency of EI in these groups was r = 0.85 (p </= 0.01). The 
      percentage of patients with a significant decrease (EI >/=1.0) among those treated 
      with standard- and low-dose trospium and solifenacin increased synchronously, 
      prompting us to suppose the absence of a direct correlation between medicine dose 
      and therapeutic effect for moderate OAB symptoms. CONCLUSION: The combination of 
      low-dose trospium and solifenacin provides good clinical and urodynamic effects 
      in elderly patients with moderate symptoms of OAB. Combination of these drugs in 
      standard doses for such patients is excessive.
FAU - Kosilov, Kirill V
AU  - Kosilov KV
AD  - Department of Adaptive Medicine, Institute of Physical Health, Far Eastern 
      Federal University, Vladivostok, Russian Federation.
FAU - Loparev, Sergey A
AU  - Loparev SA
FAU - Ivanovskaya, Marina A
AU  - Ivanovskaya MA
FAU - Kosilova, Liliya V
AU  - Kosilova LV
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20140828
PL  - Switzerland
TA  - Urol Int
JT  - Urologia internationalis
JID - 0417373
RN  - 0 (Benzilates)
RN  - 0 (Muscarinic Antagonists)
RN  - 0 (Nortropanes)
RN  - 0 (Quinuclidines)
RN  - 0 (Tetrahydroisoquinolines)
RN  - 0 (Urological Agents)
RN  - 1E6682427E (trospium chloride)
RN  - KKA5DLD701 (Solifenacin Succinate)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Benzilates/*administration & dosage/adverse effects
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Muscarinic Antagonists/*administration & dosage/adverse effects
MH  - Nortropanes/*administration & dosage/adverse effects
MH  - Quinuclidines/*administration & dosage/adverse effects
MH  - Russia
MH  - Severity of Illness Index
MH  - Sex Factors
MH  - Solifenacin Succinate
MH  - Tetrahydroisoquinolines/*administration & dosage/adverse effects
MH  - Time Factors
MH  - Treatment Outcome
MH  - Urinary Bladder/*drug effects/physiopathology
MH  - Urinary Bladder, Overactive/diagnosis/*drug therapy/physiopathology
MH  - Urodynamics/drug effects
MH  - Urological Agents/*administration & dosage/adverse effects
EDAT- 2014/08/30 06:00
MHDA- 2015/08/26 06:00
CRDT- 2014/08/30 06:00
PHST- 2014/03/03 00:00 [received]
PHST- 2014/05/15 00:00 [accepted]
PHST- 2014/08/30 06:00 [entrez]
PHST- 2014/08/30 06:00 [pubmed]
PHST- 2015/08/26 06:00 [medline]
AID - 000363658 [pii]
AID - 10.1159/000363658 [doi]
PST - ppublish
SO  - Urol Int. 2014;93(4):470-3. doi: 10.1159/000363658. Epub 2014 Aug 28.